9,134 Shares in Merck & Co., Inc. (NYSE:MRK) Purchased by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,134 shares of the company’s stock, valued at approximately $1,037,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. bought a new position in shares of Merck & Co., Inc. during the second quarter valued at $39,000. Abich Financial Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after buying an additional 179 shares during the last quarter. Quarry LP bought a new position in shares of Merck & Co., Inc. in the second quarter valued at about $42,000. Ruedi Wealth Management Inc. lifted its stake in shares of Merck & Co., Inc. by 27.7% during the second quarter. Ruedi Wealth Management Inc. now owns 397 shares of the company’s stock valued at $49,000 after acquiring an additional 86 shares during the period. Finally, Dixon Mitchell Investment Counsel Inc. acquired a new position in Merck & Co., Inc. during the 1st quarter valued at about $53,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Up 0.1 %

MRK traded up $0.11 during trading on Thursday, reaching $106.49. The company had a trading volume of 395,256 shares, compared to its average volume of 8,753,088. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. Merck & Co., Inc. has a 12 month low of $99.80 and a 12 month high of $134.63. The business’s fifty day moving average price is $113.86 and its 200 day moving average price is $121.93. The company has a market cap of $269.72 billion, a P/E ratio of 118.20, a PEG ratio of 1.55 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12. The business had revenue of $16.10 billion for the quarter, compared to analyst estimates of $15.87 billion. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.06) earnings per share. Equities analysts anticipate that Merck & Co., Inc. will post 7.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MRK. Wells Fargo & Company lowered their price target on shares of Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Merck & Co., Inc. in a research report on Thursday, October 17th. They set a “market perform” rating and a $115.00 price target for the company. Wolfe Research upgraded shares of Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, July 31st. Truist Financial lowered their price target on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Finally, Bank of America decreased their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating, nine have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $131.62.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.